{"links": [{"source": 0, "target": "t8313", "value": "None"}, {"source": 0, "target": "t8333", "value": "None"}, {"source": 0, "target": "t8374", "value": "None"}, {"source": 0, "target": "t8350", "value": "None"}, {"source": 0, "target": "t8364", "value": "None"}, {"source": 0, "target": "t8331", "value": "None"}, {"source": 0, "target": "t8320", "value": "None"}, {"source": 0, "target": "t8381", "value": "None"}, {"source": "t8313", "target": "t8314", "value": "None"}, {"source": "t8313", "target": "t8319", "value": "None"}, {"source": "t8313", "target": "t8318", "value": "None"}, {"source": "t8333", "target": "t8334", "value": "None"}, {"source": "t8333", "target": "t8335", "value": "None"}, {"source": "t8333", "target": "d25", "value": "None"}, {"source": "t8374", "target": "t8378", "value": "None"}, {"source": "t8374", "target": "t8376", "value": "None"}, {"source": "t8374", "target": "t8375", "value": "None"}, {"source": "t8374", "target": "t8377", "value": "None"}, {"source": "t8350", "target": "t8351", "value": "None"}, {"source": "t8350", "target": "t8363", "value": "None"}, {"source": "t8364", "target": "t8365", "value": "None"}, {"source": "t8364", "target": "t8369", "value": "None"}, {"source": "t8331", "target": "t8349", "value": "None"}, {"source": "t8331", "target": "t8332", "value": "None"}, {"source": "t8320", "target": "t8327", "value": "None"}, {"source": "t8320", "target": "t8321", "value": "None"}, {"source": "t8381", "target": "t8382", "value": "None"}, {"source": "t8314", "target": "t8315", "value": "None"}, {"source": "t8314", "target": "t8316", "value": "None"}, {"source": "t8334", "target": "t8336", "value": "None"}, {"source": "t8335", "target": "t8336", "value": "None"}, {"source": "t8378", "target": "t8379", "value": "None"}, {"source": "t8376", "target": "t8379", "value": "None"}, {"source": "t8375", "target": "t8379", "value": "None"}, {"source": "t8377", "target": "t8379", "value": "None"}, {"source": "t8351", "target": "t8352", "value": "None"}, {"source": "t8365", "target": "t8366", "value": "None"}, {"source": "t8365", "target": "t8367", "value": "None"}, {"source": "t8369", "target": "t8370", "value": "None"}, {"source": "t8369", "target": "t8371", "value": "None"}, {"source": "t8321", "target": "t8322", "value": "None"}, {"source": "t8382", "target": "t8383", "value": "None"}, {"source": "t8382", "target": "t8384", "value": "None"}, {"source": "t8315", "target": "t8317", "value": "None"}, {"source": "t8316", "target": "t8317", "value": "None"}, {"source": "t8336", "target": "t8337", "value": "None"}, {"source": "t8379", "target": "t8380", "value": "None"}, {"source": "t8379", "target": "d86", "value": "None"}, {"source": "t8352", "target": "t8353", "value": "None"}, {"source": "t8352", "target": "d108", "value": "None"}, {"source": "t8366", "target": "t8368", "value": "None"}, {"source": "t8367", "target": "t8368", "value": "None"}, {"source": "t8370", "target": "t8372", "value": "None"}, {"source": "t8371", "target": "t8372", "value": "None"}, {"source": "t8322", "target": "t8324", "value": "None"}, {"source": "t8322", "target": "t8323", "value": "None"}, {"source": "t8383", "target": "t8386", "value": "None"}, {"source": "t8384", "target": "t8385", "value": "None"}, {"source": "t8337", "target": "t8339", "value": "None"}, {"source": "t8337", "target": "t8341", "value": "None"}, {"source": "t8337", "target": "t8338", "value": "None"}, {"source": "t8337", "target": "t8340", "value": "None"}, {"source": "t8353", "target": "t8354", "value": "None"}, {"source": "t8368", "target": "t8373", "value": "None"}, {"source": "t8368", "target": "d167", "value": "None"}, {"source": "t8368", "target": "d297", "value": "None"}, {"source": "t8372", "target": "t8373", "value": "None"}, {"source": "t8324", "target": "t8325", "value": "None"}, {"source": "t8323", "target": "t8325", "value": "None"}, {"source": "t8385", "target": "t8386", "value": "None"}, {"source": "t8339", "target": "t8342", "value": "None"}, {"source": "t8341", "target": "t8342", "value": "None"}, {"source": "t8338", "target": "t8342", "value": "None"}, {"source": "t8340", "target": "t8342", "value": "None"}, {"source": "t8354", "target": "t8358", "value": "None"}, {"source": "t8354", "target": "t8355", "value": "None"}, {"source": "t8354", "target": "t8357", "value": "None"}, {"source": "t8354", "target": "t8356", "value": "None"}, {"source": "t8354", "target": "d181", "value": "None"}, {"source": "t8325", "target": "t8326", "value": "None"}, {"source": "t8342", "target": "t8345", "value": "None"}, {"source": "t8342", "target": "t8344", "value": "None"}, {"source": "t8342", "target": "t8343", "value": "None"}, {"source": "t8358", "target": "t8359", "value": "None"}, {"source": "t8355", "target": "t8359", "value": "None"}, {"source": "t8357", "target": "t8359", "value": "None"}, {"source": "t8356", "target": "t8359", "value": "None"}, {"source": "t8326", "target": "t8330", "value": "None"}, {"source": "t8326", "target": "t8328", "value": "None"}, {"source": "t8326", "target": "t8329", "value": "None"}, {"source": "t8345", "target": "t8346", "value": "None"}, {"source": "t8345", "target": "d232", "value": "None"}, {"source": "t8344", "target": "t8346", "value": "None"}, {"source": "t8343", "target": "t8346", "value": "None"}, {"source": "t8359", "target": "t8360", "value": "None"}, {"source": "t8359", "target": "t8361", "value": "None"}, {"source": "t8328", "target": "d222", "value": "None"}, {"source": "t8328", "target": "d118", "value": "None"}, {"source": "t8346", "target": "t8347", "value": "None"}, {"source": "t8360", "target": "t8361", "value": "None"}, {"source": "t8361", "target": "t8362", "value": "None"}, {"source": "t8347", "target": "t8348", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Chronic_obstructive_pulmonary_disease", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Chronic_obstructive_pulmonary_disease"}}, {"category": "treatment", "id": "t8313", "name": "person at risk of copd", "draggable": "true", "value": {"name": "person at risk of copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person at risk of copd", "drug": {}}}, {"category": "treatment", "id": "t8333", "name": "treatment at home or in hospital?", "draggable": "true", "value": {"name": "treatment at home or in hospital?", "type": "treatment related", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:treatment at home or in hospital?head:Treatment at home or in hospital?Factors to consider when deciding where to manage exacerbations should be used to assess the need to treat patients in hospital.Hospital-at-home and assisted-discharge schemes are safe and effective and should be used as an alternative way of caring for patients with exacerbations of COPD who would otherwise need to be admitted or stay in hospital. The multi-professional team required to operate these schemes should include allied heath professionals with experience in managing COPD, and may include nurses, physiotherapists, occupational therapists and generic health workers.There are currently insufficient data to make firm recommendations about which patients with an exacerbation are most suitable for hospital-at-home or early discharge. Patient selection should depend on the resources available and absence of factors associated with a worse prognosis, for example, acidosis.Patients  preferences about treatment at home or in hospital should be considered.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {"alli": "DB01083"}}}, {"category": "treatment", "id": "t8374", "name": "person with stable copd", "draggable": "true", "value": {"name": "person with stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with stable copd", "drug": {}}}, {"category": "treatment", "id": "t8350", "name": "person with stable copd", "draggable": "true", "value": {"name": "person with stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with stable copd", "drug": {}}}, {"category": "treatment", "id": "t8364", "name": "person with stable copd", "draggable": "true", "value": {"name": "person with stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with stable copd", "drug": {}}}, {"category": "treatment", "id": "t8331", "name": "person with exacerbation of copd", "draggable": "true", "value": {"name": "person with exacerbation of copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with exacerbation of copd", "drug": {}}}, {"category": "treatment", "id": "t8320", "name": "person with suspected or previously diagnosed copd", "draggable": "true", "value": {"name": "person with suspected or previously diagnosed copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected or previously diagnosed copd", "drug": {}}}, {"category": "treatment", "id": "t8381", "name": "person with stable copd", "draggable": "true", "value": {"name": "person with stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with stable copd", "drug": {}}}, {"category": "treatment", "id": "t8314", "name": "diagnosis and assessment", "draggable": "true", "value": {"name": "diagnosis and assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnosis and assessment", "drug": {}}}, {"category": "treatment", "id": "t8319", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t8318", "name": "multidisciplinary team", "draggable": "true", "value": {"name": "multidisciplinary team", "type": "treatment related", "time": "", "intention": "", "description": "title:multidisciplinary teamhead:Multidisciplinary teamCOPD care should be delivered by a multidisciplinary team. The following functions should be considered when defining the activity of the multidisciplinary team: assessing patients (including performing spirometry, assessing the need for oxygen, the need for aids for daily living and the appropriateness of delivery systems for inhaled therapy) care and treatment of patients (including non-invasive ventilation, pulmonary rehabilitation, hospital-at-home/early discharge schemes, providing palliative care, identifying and managing anxiety and depression, advising patients on relaxation techniques, dietary issues, exercise, social security benefits and travel) advising patients on self-management strategies identifying and monitoring patients at high risk of exacerbations and undertaking activities which aim to avoid emergency admissions advising patients on exercise education of patients and other health professionals.It is recommended that respiratory nurse specialists form part of the multidisciplinary COPD team.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8334", "name": "investigations in primary care", "draggable": "true", "value": {"name": "investigations in primary care", "type": "treatment related", "time": "", "intention": "", "description": "title:investigations in primary carehead:Investigations in primary careIn patients who have their exacerbation managed in primary care: sending sputum samples for culture is not recommended in routine practice pulse oximetry is of value if there are clinical features of a severe exacerbation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8335", "name": "investigations in hospital", "draggable": "true", "value": {"name": "investigations in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:investigations in hospitalhead:Investigations in hospitalWhen the patient arrives at hospital, arterial blood gases should be measured and the inspired oxygen concentration noted in all patients with an exacerbation of COPD. Arterial blood gas measurements should be repeated regularly, according to the response to treatment.In all patients with an exacerbation referred to hospital: a chest radiograph should be obtained arterial blood gas tensions should be measured and the inspired oxygen concentration should be recorded an ECG should be recorded (to exclude comorbidities) a full blood count should be performed and urea and electrolyte concentrations should be measured a theophylline level should be measured in patients on theophylline therapy at admission if sputum is purulent, a sample should be sent for microscopy and culture blood cultures should be taken if the patient is pyrexial.NICE has published a medtech innovation briefing on the needle-free arterial non-injectable connector.subhead:Procalcitonin testing for diagnosing and monitoring sepsisThe following recommendations are from NICE diagnostics guidance on procalcitonin testing for diagnosing and monitoring sepsis.The procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay or VIDAS BRAHMS PCT assay) show promise but there is currently insufficient evidence to recommend their routine adoption in the NHS. Further research on procalcitonin tests is recommended for guiding decisions to: stop antibiotic treatment in people with confirmed or highly suspected sepsis in the intensive care unit or start and stop antibiotic treatment in people with suspected bacterial infection presenting to the emergency department.Centres currently using procalcitonin tests to guide these decisions are encouraged to participate in research and data collection (see section 6.25 of NICE diagnostics guidance 18).See NICE s recommendations on sepsis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101DG18", "drug": {}}}, {"category": "treatment", "id": "t8378", "name": "theophylline", "draggable": "true", "value": {"name": "theophylline", "type": "treatment related", "time": "", "intention": "", "description": "title:theophyllinehead:TheophyllineTheophylline should only be used after a trial of short-acting bronchodilators and long-acting bronchodilators, or in patients who are unable to use inhaled therapy, as there is a need to monitor plasma levels and interactions.Particular caution needs to be taken with the use of theophylline in older people because of differences in pharmacokinetics, the increased likelihood of comorbidities and the use of other medications.The effectiveness of the treatment with theophylline should be assessed by improvements in symptoms, activities of daily living, exercise capacity and lung function.The dose of theophylline prescribed should be reduced at the time of an exacerbation if macrolide or fluroquinolone antibiotics (or other drugs known to interact) are prescribed.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8376", "name": "mucolytics", "draggable": "true", "value": {"name": "mucolytics", "type": "treatment related", "time": "", "intention": "", "description": "title:mucolyticshead:Mucolytics Mucolytic drug therapy should be considered in patients with a chronic cough productive of sputum.Mucolytic therapy should be continued if there is symptomatic improvement (for example, reduction in frequency of cough and sputum production).Do not routinely use mucolytic drugs to prevent exacerbations in people with stable COPD.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8375", "name": "corticosteroids", "draggable": "true", "value": {"name": "corticosteroids", "type": "treatment related", "time": "", "intention": "", "description": "title:corticosteroidshead:CorticosteroidsMaintenance use of oral corticosteroid therapy in COPD is not normally recommended. Some patients with advanced COPD may require maintenance oral corticosteroids when these cannot be withdrawn following an exacerbation. In these cases, the dose of oral corticosteroids should be kept as low as possible.Patients treated with long-term oral corticosteroid therapy should be monitored for the development of osteoporosis and given appropriate prophylaxis. Patients over the age of 65 should be started on prophylactic treatment, without monitoring.For further information, see NICE s recommendations on osteoporosis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8377", "name": "roflumilast", "draggable": "true", "value": {"name": "roflumilast", "type": "treatment related", "time": "", "intention": "", "description": "title:roflumilasthead:RoflumilastThe following recommendations are from NICE technology appraisal guidance on roflumilast for the management of severe chronic obstructive pulmonary disease.Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if: the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.Treatment with roflumilast should be started by a specialist in respiratory medicine.These recommendations are not intended to affect treatment with roflumilast that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.NICE has written information for the public on roflumilast.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. TA461", "drug": {}}}, {"category": "treatment", "id": "t8351", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportsubhead:Education programmesThere are significant differences in the response of patients with COPD and asthma to education programmes. Programmes designed for asthma should not be used in COPD.Specific educational packages should be developed for patients with COPD. Suggested topics for inclusion are listed in appendix C of the full guideline. The packages should take account of the different needs of patients at different stages of their disease.Patients with moderate and severe COPD should be made aware of the technique of NIV. Its benefits and limitations should be explained so that if it is ever necessary in the future they will be aware of these issues (see non-invasive ventilation).subhead:Advice on travelAll patients on LTOT planning air travel should be assessed in line with the BTS recommendationsBritish Thoracic Society Standards of Care Committee (2002) Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 57(4): 289\u2013304..All patients with an FEV1 < 50% predicted who are planning air travel should be assessed in line with the BTS recommendations.All patients known to have bullous disease should be warned that they are at a theoretically increased risk of developing a pneumothorax during air travel.subhead:Advice on divingScuba diving is not generally recommended for patients with COPD. Advise people with queries to seek specialist advice.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8363", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t8365", "name": "choice of drug", "draggable": "true", "value": {"name": "choice of drug", "type": "treatment related", "time": "", "intention": "", "description": "title:choice of drug", "drug": {}}}, {"category": "treatment", "id": "t8369", "name": "delivery system", "draggable": "true", "value": {"name": "delivery system", "type": "treatment related", "time": "", "intention": "", "description": "title:delivery system", "drug": {}}}, {"category": "treatment", "id": "t8349", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t8332", "name": "self management", "draggable": "true", "value": {"name": "self management", "type": "treatment related", "time": "", "intention": "", "description": "title:self-managementhead:Self-managementPatients at risk of having an exacerbation of COPD should be given self-management advice that encourages them to respond promptly to the symptoms of an exacerbation. Patients should be encouraged to respond promptly to the symptoms of an exacerbation by: starting oral corticosteroid therapy if their increased breathlessness interferes with activities of daily living (unless contraindicated) starting antibiotic therapy if their sputum is purulent adjusting their bronchodilator therapy to control their symptoms.Patients at risk of having an exacerbation of COPD should be given a course of antibiotic and corticosteroid tablets to keep at home for use as part of a self-management strategy (see corticosteroids for details of dosage levels of prednisolone).The appropriate use of these tablets should be monitored.Patients given self-management plans should be advised to contact a healthcare professional if they do not improve.For information on effective antimicrobial medicine use see NICE s recommendations on antimicrobial stewardship.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8327", "name": "training and skills", "draggable": "true", "value": {"name": "training and skills", "type": "treatment related", "time": "", "intention": "", "description": "title:training and skillshead:Training and skillsAll health professionals involved in the care of people with COPD should have access to spirometry and be competent in the interpretation of the results. Spirometry can be performed by any healthcare worker who has undergone appropriate training and who keeps his or her skills up to date.Spirometry services should be supported by quality control processes.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard1Diagnosis with spirometrySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8321", "name": "symptoms", "draggable": "true", "value": {"name": "symptoms", "type": "treatment related", "time": "", "intention": "", "description": "title:symptomshead:Symptoms A diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally smoking) and who present with one or more of the following symptoms: exertional breathlessness chronic cough regular sputum production frequent winter  bronchitis  wheeze.Patients in whom a diagnosis of COPD is considered should also be asked about the presence of the following factors: weight loss effort intolerance waking at night ankle swelling fatigue occupational hazards chest pain haemoptysis.NB These last two symptoms are uncommon in COPD and raise the possibility of alternative diagnoses.See what NICE has to say on lung and pleural cancers in terms of suspected cancer recognition and referral.subhead:BreathlessnessOne of the primary symptoms of COPD is breathlessness. The Medical Research Council dyspnoea scale should be used to grade the breathlessness according to the level of exertion required to elicit it.Patients should be regularly asked about their ability to undertake activities of daily living and how breathless they become when doing these.subhead:Anxiety and depressionHealthcare professionals should be alert to the presence of depression in patients with COPD. The presence of anxiety and depression should be considered in patients: who are hypoxic  who have severe dyspnoea who have been seen at or admitted to a hospital with an exacerbation of COPD.See NICE s recommendations on generalised anxiety disorder and care for adults with depression, which includes recommendations on depression in adults with a chronic physical health problem. Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard1Diagnosis with spirometrySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8382", "name": "risks of oxygen therapy", "draggable": "true", "value": {"name": "risks of oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:risks of oxygen therapyhead:Risks of oxygen therapyClinicians should be aware that inappropriate oxygen therapy in people with COPD may cause respiratory depression.Patients should be warned about the risks of fire and explosion if they continue to smoke when prescribed oxygen.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8315", "name": "management", "draggable": "true", "value": {"name": "management", "type": "treatment related", "time": "", "intention": "", "description": "title:management", "drug": {}}}, {"category": "treatment", "id": "t8316", "name": "managing exacerbations", "draggable": "true", "value": {"name": "managing exacerbations", "type": "treatment related", "time": "", "intention": "", "description": "title:managing exacerbations", "drug": {}}}, {"category": "treatment", "id": "t8336", "name": "delivery systems for inhaled therapy", "draggable": "true", "value": {"name": "delivery systems for inhaled therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:delivery systems for inhaled therapyhead:Delivery systems for inhaled therapyBoth nebulisers and hand-held inhalers can be used to administer inhaled therapy during exacerbations of COPD.The choice of delivery system should reflect the dose of drug required, the ability of the patient to use the device and the resources available to supervise the administration of the therapy.Patients should be changed to hand-held inhalers as soon as their condition has stabilised because this may permit earlier discharge from hospital.If a patient is hypercapnic or acidotic the nebuliser should be driven by compressed air, not oxygen (to avoid worsening hypercapnia). If oxygen therapy is needed it should be administered simultaneously by nasal cannulae.The driving gas for nebulised therapy should always be specified in the prescription.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8379", "name": "drugs not recommended", "draggable": "true", "value": {"name": "drugs not recommended", "type": "treatment related", "time": "", "intention": "beta-carotene\nit is used to treat or prevent vitamin a deficiency.", "description": "title:drugs not recommendedhead:Drugs not recommendedsubhead:AntibioticsThere is insufficient evidence to recommend prophylactic antibiotic therapy in the management of stable COPD.subhead:AntioxidantsTreatment with alpha-tocopherol and beta-carotene supplements, alone or in combination, is not recommended.subhead:AntitussivesAntitussive therapy should not be used in the management of stable COPD.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8352", "name": "smoking", "draggable": "true", "value": {"name": "smoking", "type": "information and support", "time": "", "intention": "bupropion\nbupropion is used to treat depression and to prevent depression in patients with seasonal affective disorder (sad), which is sometimes called winter depression. it is also used as part of a support program to help people stop smoking.\nappropriate studies have not been performed on the relationship of age to the effects of bupropion in the pediatric population. however, children are more sensitive to the effects of bupropion than adults when used for treating depression. use of bupropion to treat depression in children is not recommended. safety and efficacy of bupropion to help stop smoking have not been established in children.\nalthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. in these cases, your doctor may want to change the dose, or other precautions may be necessary. when you are taking bupropion, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. the following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.\nusing bupropion with any of the following is usually not recommended, but may be unavoidable in some cases. if used together, your doctor may change the dose or how often you use bupropion, or give you special instructions about the use of food, alcohol, or tobacco.", "description": "title:smokinghead:SmokingAn up-to-date smoking history, including pack years smoked (number of cigarettes smoked per day, divided by 20, multiplied by the number of years smoked), should be documented for everyone with COPD.All COPD patients still smoking, regardless of age, should be encouraged to stop, and offered help to do so, at every opportunity. Unless contraindicated, offer NRT, varenicline or bupropion, as appropriate, to people who are planning to stop smoking combined with an appropriate support programme to optimise smoking quit rates for people with COPD. For more information on helping people stop smoking, see NICE s recommendations on stop smoking interventions and services. subhead:VareniclineThe following recommendations are from NICE technology appraisal guidance on varenicline for smoking cessation. Varenicline is recommended within its licensed indications as an option for smokers who have expressed a desire to quit smoking.Varenicline should normally be prescribed only as part of a programme of behavioural support.NICE has written information for the public on varenicline.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.Smoking: supporting people to stop2Referral to smoking cessation services3Behavioural support with pharmacotherapy4PharmacotherapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101TA123", "drug": {"bupropion": "DB01156"}}}, {"category": "treatment", "id": "t8366", "name": "short acting bronchodilators", "draggable": "true", "value": {"name": "short acting bronchodilators", "type": "treatment related", "time": "", "intention": "", "description": "title:short-acting bronchodilatorshead:Short-acting bronchodilatorsShort-acting bronchodilators, as necessary, should be the initial empirical treatment for the relief of breathlessness and exercise limitation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8367", "name": "corticosteroids", "draggable": "true", "value": {"name": "corticosteroids", "type": "treatment related", "time": "", "intention": "", "description": "title:corticosteroidshead:CorticosteroidsOral corticosteroid reversibility tests do not predict response to inhaled corticosteroid therapy and should not be used to identify which patients should be prescribed inhaled corticosteroids.Be aware of the potential risk of developing side effects (including non-fatal pneumonia) in people with COPD treated with inhaled corticosteroids and be prepared to discuss with patients.For further information, see NICE s recommendations on pneumonia.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8370", "name": "inhalers", "draggable": "true", "value": {"name": "inhalers", "type": "treatment related", "time": "", "intention": "", "description": "title:inhalershead:InhalersIn most cases bronchodilator therapy is best administered using a hand-held inhaler device (including a spacer device if appropriate).If the patient is unable to use a particular device satisfactorily, it is not suitable for him or her, and an alternative should be found.Inhalers should be prescribed only after patients have received training in the use of the device and have demonstrated satisfactory technique.Patients should have their ability to use an inhaler device regularly assessed by a competent healthcare professional and, if necessary, should be re-taught the correct technique.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard2Inhaler techniqueSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8371", "name": "spacers", "draggable": "true", "value": {"name": "spacers", "type": "treatment related", "time": "", "intention": "", "description": "title:spacershead:SpacersThe spacer should be compatible with the patient s metered-dose inhaler.It is recommended that spacers are used in the following way: the drug is administered by repeated single actuations of the metered-dose inhaler into the spacer, with each followed by inhalation there should be minimal delay between inhaler actuation and inhalation tidal breathing can be used as it is as effective as single breaths.Spacers should be cleaned no more than monthly as more frequent cleaning affects their performance (because of a build up of static). They should be cleaned with water and washing-up liquid and allowed to air dry. The mouthpiece should be wiped clean of detergent before use.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8322", "name": "spirometry", "draggable": "true", "value": {"name": "spirometry", "type": "treatment related", "time": "", "intention": "", "description": "title:spirometryhead:SpirometrySpirometry should be performed in patients who are over 35, current or ex-smokers, and have a chronic cough.Spirometry should be considered in patients with chronic bronchitis. A significant proportion of these will go on to develop airflow limitationCelli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 23(6): 932\u201346..Spirometry should be performed: at the time of diagnosis to reconsider the diagnosis, if patients show an exceptionally good response to treatment.Measure post-bronchodilator spirometry to confirm the diagnosis of COPD. Consider alternative diagnoses or investigations in: older people without typical symptoms of COPD where the FEV1/FVC ratio is < 0.7 younger people with symptoms of COPD where the FEV1/FVC ratio is \u2265 0.7.It is recommended that ERS 1993 reference valuesQuanjer PH, Tammeling GJ, Cotes JE et al. (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. European Respiratory Journal (Suppl) 16: 5\u201340. are used but it is recognised that these values may lead to under-diagnosis in older people and are not applicable in black and Asian populationsDefinitive spirometry reference values are not currently available for all ethnic populations. The GDG was aware of ongoing research in this area..In most patients routine spirometric reversibility testing is not necessary as a part of the diagnostic process or to plan initial therapy with bronchodilators or corticosteroids. It may be unhelpful or misleading because: repeated FEV1 measurements can show small spontaneous fluctuations the results of a reversibility test performed on different occasions can be inconsistent and not reproducible over-reliance on a single reversibility test may be misleading unless the change in FEV1 is greater than 400 ml the definition of the magnitude of a significant change is purely arbitrary response to long-term therapy is not predicted by acute reversibility testing.NICE has published a medtech innovation briefing on Smart One for measuring lung function.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard1Diagnosis with spirometrySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8383", "name": "short burst oxygen therapy", "draggable": "true", "value": {"name": "short burst oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:short-burst oxygen therapyhead:Short-burst oxygen therapyShort-burst oxygen therapy should only be considered for episodes of severe breathlessness in patients with COPD not relieved by other treatments.Short-burst oxygen therapy should only continue to be prescribed if an improvement in breathlessness following therapy has been documented.When indicated, short-burst oxygen should be provided from cylinders.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8384", "name": "long term oxygen therapy", "draggable": "true", "value": {"name": "long term oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:long-term oxygen therapyhead:Long-term oxygen therapyLTOT is indicated in patients with COPD who have a PaO2 less than 7.3 kPa when stable or a PaO2 greater than 7.3 and less than 8 kPa when stable and one of: secondary polycythaemia, nocturnal hypoxaemia (SaO2 less than 90% for more than 30% of the time), peripheral oedema or pulmonary hypertension.To get the benefits of LTOT patients should breathe supplemental oxygen for at least 15 hours per day. Greater benefits are seen in patients receiving oxygen for 20 hours per day.The need for oxygen therapy should be assessed in: all patients with very severe airflow obstruction (FEV1 < 30% predicted) patients with cyanosis patients with polycythaemia patients with peripheral oedema patients with a raised jugular venous pressure patients with oxygen saturations less than or equal to 92% breathing air.Assessment should also be considered in patients with severe airflow obstruction (FEV1 30\u201349% predicted).To ensure all patients eligible for LTOT are identified, pulse oximetry should be available in all healthcare settings.The assessment of patients for LTOT should comprise the measurement of arterial blood gases on two occasions at least 3 weeks apart in patients who have a confident diagnosis of COPD, who are receiving optimum medical management and whose COPD is stable.Patients receiving LTOT should be reviewed at least once per year by practitioners familiar with LTOT and this review should include pulse oximetry.Oxygen concentrators should be used to provide the fixed supply at home for LTOT.subhead:Nasal Alar SpO2 sensorNICE has published a medtech innovation briefing on Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard3Assessment for long-term oxygen therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8317", "name": "palliative care", "draggable": "true", "value": {"name": "palliative care", "type": "treatment related", "time": "", "intention": "", "description": "title:palliative carehead:Palliative careOpioids should be used when appropriate to palliate breathlessness in patients with end-stage COPD which is unresponsive to other medical therapy.Benzodiazepines, tricyclic antidepressants, major tranquillisers and oxygen should also be used when appropriate for breathlessness in patients with end-stage COPD unresponsive to other medical therapy.Patients with end-stage COPD and their family and carers should have access to the full range of services offered by multidisciplinary palliative care teams, including admission to hospices.See what NICE says on end of life care for people with life-limiting conditions.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8337", "name": "treatment options", "draggable": "true", "value": {"name": "treatment options", "type": "treatment related", "time": "", "intention": "", "description": "title:treatment options", "drug": {}}}, {"category": "treatment", "id": "t8380", "name": "back to managing stable copd", "draggable": "true", "value": {"name": "back to managing stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:back to managing stable copd", "drug": {}}}, {"category": "treatment", "id": "t8353", "name": "vaccinations", "draggable": "true", "value": {"name": "vaccinations", "type": "treatment related", "time": "", "intention": "", "description": "title:vaccinationshead:VaccinationsPneumococcal vaccination and an annual influenza vaccination should be offered to all patients with COPD as recommended by the Chief Medical Officer.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8368", "name": "long acting bronchodilators", "draggable": "true", "value": {"name": "long acting bronchodilators", "type": "treatment related", "time": "", "intention": "aclidinium bromide\n", "description": "title:long-acting bronchodilatorshead:Long-acting bronchodilatorsThe effectiveness of bronchodilator therapy should not be assessed by lung function alone but should include a variety of other measures such as improvement in symptoms, activities of daily living, exercise capacity, and rapidity of symptom relief.Offer once-daily LAMA in preference to four-times-daily SAMA to people with stable COPD who remain breathless or have exacerbations despite using short-acting bronchodilators as required, and in whom a decision has been made to commence regular maintenance bronchodilator therapy with a muscarinic antagonist. The British National Formulary states that a SAMA should be discontinued when a LAMA is started.In people with stable COPD who remain breathless or have exacerbations despite using short-acting bronchodilators as required, offer the following as maintenance therapy: if FEV1 \u2265 50% predicted: either LABA or LAMA if FEV1 < 50% predicted: either LABA with an ICS in a combination inhaler, or LAMA.In people with stable COPD and an FEV1 \u2265 50% who remain breathless or have exacerbations despite maintenance therapy with a LABA: consider LABA + ICS in a combination inhaler consider LAMA in addition to LABA where ICS is declined or not tolerated.Offer LAMA in addition to LABA + ICS to people with COPD who remain breathless or have exacerbations despite taking LABA + ICS, irrespective of their FEV1.Consider LABA + ICS in a combination inhaler in addition to LAMA for people with stable COPD who remain breathless or have exacerbations despite maintenance therapy with LAMA irrespective of their FEV1.The choice of drug(s) should take into account the person s symptomatic response and preference, and the drug s potential to reduce exacerbations, its side effects and cost.subhead:Evidence summariesNICE has published evidence summaries on: chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) chronic obstructive pulmonary disease: aclidinium/formoterol chronic obstructive pulmonary disease: olodaterol chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol chronic obstructive pulmonary disease: glycopyrronium bromide chronic obstructive pulmonary disease: aclidinium bromide.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {"fluticasone": "DB13867"}}}, {"category": "treatment", "id": "t8372", "name": "nebulisers", "draggable": "true", "value": {"name": "nebulisers", "type": "treatment related", "time": "", "intention": "", "description": "title:nebulisershead:NebulisersPatients with distressing or disabling breathlessness despite maximal therapy using inhalers should be considered for nebuliser therapy.Nebulised therapy should not continue to be prescribed without assessing and confirming that one or more of the following occurs: a reduction in symptoms an increase in the ability to undertake activities of daily living an increase in exercise capacity an improvement in lung function.Nebulised therapy should not be prescribed without an assessment of the patient s and/or carer s ability to use it.A nebuliser system that is known to be efficient should be used. Once available, CEN data should be used to assess efficiency.Patients should be offered a choice between a facemask and a mouthpiece to administer their nebulised therapy, unless the drug specifically requires a mouthpiece (for example, anticholinergic drugs).If nebuliser therapy is prescribed, the patient should be provided with equipment, servicing, advice and support.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8324", "name": "severity assessment", "draggable": "true", "value": {"name": "severity assessment", "type": "treatment related", "time": "", "intention": "", "description": "title:severity assessmenthead:Severity assessmentBe aware that disability in COPD can be poorly reflected in the FEV1. A more comprehensive assessment of severity includes the degree of airflow obstruction and disability, the frequency of exacerbations and the following known prognostic factors: FEV1 TLCO breathlessness (MRC scale) health status exercise capacity (for example, 6-minute walk test) BMI partial pressure of oxygen in arterial blood (PaO2) cor pulmonale.Calculate the BODE index to assess prognosis where its component information is currently available.Severity of airflow obstruction should be assessed according to the reduction in FEV1.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8323", "name": "additional investigations", "draggable": "true", "value": {"name": "additional investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:additional investigationshead:Additional investigationsAt the time of their initial diagnostic evaluation in addition to spirometry all patients should have: a chest radiograph to exclude other pathologies a full blood count to identify anaemia or polycythaemia BMI calculated.Additional investigations should be performed to aid management in some circumstances.BMI should be calculated in patients with COPD: the normal range for BMI is 20 to less than 25 (not reviewed as part of the 2010 guideline update; NICE guideline CG43 [2006] on obesity states a healthy range is 18.5 to 24.9 kg/m2, but this may not be appropriate for people with COPD). In older patients attention should also be paid to changes in weight, particularly if the change is more than 3 kg.Clinicians involved in the care of people with COPD should assess their need for occupational therapy using validated tools.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8386", "name": "back to managing stable copd", "draggable": "true", "value": {"name": "back to managing stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:back to managing stable copd", "drug": {}}}, {"category": "treatment", "id": "t8385", "name": "ambulatory oxygen therapy", "draggable": "true", "value": {"name": "ambulatory oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:ambulatory oxygen therapyhead:Ambulatory oxygen therapyAmbulatory oxygen therapy should only be prescribed after an appropriate assessment has been performed by a specialist. The purpose of the assessment is to assess the extent of desaturation, and the improvement in exercise capacity with supplemental oxygen, and the oxygen flow rate required to correct desaturation.People who are already on LTOT who wish to continue with oxygen therapy outside the home, and who are prepared to use it, should have ambulatory oxygen prescribed.Ambulatory oxygen therapy should be considered in patients who have exercise desaturation, are shown to have an improvement in exercise capacity and/or dyspnoea with oxygen, and have the motivation to use oxygen.Ambulatory oxygen therapy is not recommended in COPD if PaO2 is greater than 7.3 kPa and there is no exercise desaturation.Small light-weight cylinders, oxygen-conserving devices and portable liquid oxygen systems should be available for the treatment of patients with COPD.A choice about the nature of equipment prescribed should take account of the hours of ambulatory oxygen use required by the patient and the oxygen flow rate required.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8339", "name": "corticosteroids", "draggable": "true", "value": {"name": "corticosteroids", "type": "treatment related", "time": "", "intention": "", "description": "title:corticosteroidshead:Corticosteroids In the absence of significant contraindications oral corticosteroids should be used, in conjunction with other therapies, in all patients admitted to hospital with an exacerbation of COPD. In the absence of significant contraindications, oral corticosteroids should be considered in patients in the community who have an exacerbation with a significant increase in breathlessness which interferes with daily activities.Patients requiring corticosteroid therapy should be encouraged to present early to get maximum benefits (see self-management).Prednisolone 30 mg orally should be prescribed for 7 to 14 days.It is recommended that a course of corticosteroid treatment should not be longer than 14 days as there is no advantage in prolonged therapy.For guidance on stopping oral corticosteroid therapy it is recommended that clinicians refer to guidance on glucocorticoid therapy from the British National Formulary.Osteoporosis prophylaxis should be considered in patients requiring frequent courses of oral corticosteroids.Patients should be made aware of the optimum duration of treatment and the adverse effects of prolonged therapy.Patients, particularly those discharged from hospital, should be given clear instructions about why, when and how to stop their corticosteroid treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8341", "name": "physiotherapy", "draggable": "true", "value": {"name": "physiotherapy", "type": "treatment related", "time": "", "intention": "", "description": "title:physiotherapyhead:PhysiotherapyPhysiotherapy using positive expiratory pressure masks should be considered for selected patients with exacerbations of COPD, to help with clearing sputum.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8338", "name": "antibiotics", "draggable": "true", "value": {"name": "antibiotics", "type": "treatment related", "time": "", "intention": "", "description": "title:antibioticshead:Antibiotics Antibiotics should be used to treat exacerbations of COPD associated with a history of more purulent sputum. Patients with exacerbations without more purulent sputum do not need antibiotic therapy unless there is consolidation on a chest radiograph or clinical signs of pneumonia.Initial empirical treatment should be an aminopenicillin, a macrolide, or a tetracycline. When initiating empirical antibiotic treatment prescribers should always take account of any guidance issued by their local microbiologists.When sputum has been sent for culture, the appropriateness of antibiotic treatment should be checked against laboratory culture and sensitivities when they become available.See NICE s recommendations on pneumonia.For information on effective antimicrobial medicine use see NICE s recommendations on antimicrobial stewardship.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8340", "name": "oxygen therapy", "draggable": "true", "value": {"name": "oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:oxygen therapyhead:Oxygen therapy The oxygen saturation should be measured in patients with an exacerbation of COPD, if there are no facilities to measure arterial blood gases.If necessary, oxygen should be given to keep the SaO2 within the individualised target range (refer to local protocols).Pulse oximeters should be available to all healthcare professionals involved in the care of patients with exacerbations of COPD and they should be trained in their use. Clinicians should be aware that pulse oximetry gives no information about the PaCO2 or pH.subhead:Nasal Alar SpO2 sensorNICE has published a medtech innovation briefing on Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard6Emergency oxygen during an exacerbationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8354", "name": "pulmonary rehabilitation", "draggable": "true", "value": {"name": "pulmonary rehabilitation", "type": "treatment related", "time": "", "intention": "commit\nnicotine oral chewing gum and lozenges are used to help you stop smoking. nicotine is absorbed from the gum or lozenge in the mouth and enters the blood stream. this replaces the nicotine you would get from smoking and makes the withdrawal effects from not smoking less severe. the amount of nicotine is decreased over time until use is stopped.\nalthough certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. in these cases, your doctor may want to change the dose, or other precautions may be necessary. tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [otc]) medicine.", "description": "title:pulmonary rehabilitationhead:Pulmonary rehabilitationPulmonary rehabilitation should be made available to all appropriate people with COPD including those who have had a recent hospitalisation for an acute exacerbation. Pulmonary rehabilitation should be offered to all patients who consider themselves functionally disabled by COPD (usually MRC grade 3 and above). Pulmonary rehabilitation is not suitable for patients who are unable to walk, have unstable angina or who have had a recent myocardial infarction.For pulmonary rehabilitation programmes to be effective, and to improve concordance, they should be held at times that suit patients, and in buildings that are easy for patients to get to and have good access for people with disabilities. Places should be available within a reasonable time of referral.Pulmonary rehabilitation programmes should include multicomponent, multidisciplinary interventions, which are tailored to the individual patient s needs. The rehabilitation process should incorporate a programme of physical training, disease education, nutritional, psychological and behavioural intervention.Patients should be made aware of the benefits of pulmonary rehabilitation and the commitment required to gain these.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard4Pulmonary rehabilitation for stable COPD and exercise limitation5Pulmonary rehabilitation after an acute exacerbationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {"commit": "DB00184"}}}, {"category": "treatment", "id": "t8373", "name": "back to managing stable copd", "draggable": "true", "value": {"name": "back to managing stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:back to managing stable copd", "drug": {}}}, {"category": "treatment", "id": "t8325", "name": "differentiating between copd and asthma", "draggable": "true", "value": {"name": "differentiating between copd and asthma", "type": "treatment related", "time": "", "intention": "", "description": "title:differentiating between copd and asthmahead:Differentiating between COPD and asthmaCOPD and asthma are frequently distinguishable on the basis of history (and examination) in untreated patients presenting for the first time. Features from the history and examination should be used to differentiate COPD from asthma whenever possible (see clinical features differentiating COPD and asthma).Longitudinal observation of patients (whether using spirometry, peak flow or symptoms) should also be used to help differentiate COPD from asthma.To help resolve cases where diagnostic doubt remains, or both COPD and asthma are present, the following findings should be used to help identify asthma: a large (> 400 ml) response to bronchodilators a large (> 400 ml) response to 30 mg oral prednisolone daily for 2 weeks serial peak flow measurements showing 20% or greater diurnal or day-to-day variability.Clinically significant COPD is not present if the FEV1 and FEV1/FVC ratio return to normal with drug therapy.If diagnostic uncertainty remains, referral for more detailed investigations, including imaging and measurement of TLCO, should be considered.If patients report a marked improvement in symptoms in response to inhaled therapy, the diagnosis of COPD should be reconsidered.For further information, see NICE s recommendations on asthma.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8342", "name": "hospital only", "draggable": "true", "value": {"name": "hospital only", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:hospital only", "drug": {}}}, {"category": "treatment", "id": "t8358", "name": "physiotherapy", "draggable": "true", "value": {"name": "physiotherapy", "type": "treatment related", "time": "", "intention": "", "description": "title:physiotherapyhead:Physiotherapy If patients have excessive sputum, they should be taught: the use of positive expiratory pressure masks active cycle of breathing techniques.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8355", "name": "inhaled therapy", "draggable": "true", "value": {"name": "inhaled therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:inhaled therapy", "drug": {}}}, {"category": "treatment", "id": "t8357", "name": "oxygen therapy", "draggable": "true", "value": {"name": "oxygen therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:oxygen therapy", "drug": {}}}, {"category": "treatment", "id": "t8356", "name": "oral therapy", "draggable": "true", "value": {"name": "oral therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:oral therapy", "drug": {}}}, {"category": "treatment", "id": "t8326", "name": "when to refer", "draggable": "true", "value": {"name": "when to refer", "type": "treatment related", "time": "", "intention": "", "description": "title:when to referhead:When to refer It is recommended that referrals for specialist advice are made when clinically indicated. Referral may be appropriate at all stages of the disease and not solely in the most severely disabled patients (see reasons for referral).Patients who are referred do not always have to be seen by a respiratory physician. In some cases they may be seen by members of the COPD team who have appropriate training and expertise.Patients identified as having alpha-1 antitrypsin deficiency should be offered the opportunity to be referred to a specialist centre to discuss the clinical management of this condition.BMI should be calculated in patients with COPD: If the BMI is abnormal (high or low), or changing over time, the patient should be referred for dietetic advice.Patients disabled by COPD should be considered for referral for assessment by a social services department.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8345", "name": "non invasive ventilation and doxapram", "draggable": "true", "value": {"name": "non invasive ventilation and doxapram", "type": "treatment related", "time": "", "intention": "doxapram\na. when the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs.\nexercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and cns depression due to drug overdosage.", "description": "title:non-invasive ventilation and doxapramhead:Non-invasive ventilation and doxapramAdequately treated patients with chronic hypercapnic respiratory failure who have required assisted ventilation (whether invasive or non-invasive) during an exacerbation or who are hypercapnic or acidotic on LTOT should be referred to a specialist centre for consideration of long-term NIV.NIV should be used as the treatment of choice for persistent hypercapnic ventilatory failure during exacerbations despite optimal medical therapy.It is recommended that NIV should be delivered in a dedicated setting with staff who have been trained in its application, who are experienced in its use and who are aware of its limitations.When patients are started on NIV there should be a clear plan covering what to do in the event of deterioration and ceilings of therapy should be agreed.It is recommended that doxapram is used only when NIV is either unavailable or considered inappropriate.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard7Non-invasive ventilationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {"doxapram": "DB00561"}}}, {"category": "treatment", "id": "t8344", "name": "invasive ventilation", "draggable": "true", "value": {"name": "invasive ventilation", "type": "treatment related", "time": "", "intention": "", "description": "title:invasive ventilationhead:Invasive ventilationPatients with exacerbations of COPD should receive treatment on intensive care units, including invasive ventilation when this is thought to be necessary.During exacerbations of COPD, functional status, BMI, requirement for oxygen when stable, comorbidities and previous admissions to intensive care units should be considered, in addition to age and FEV1, when assessing suitability for intubation and ventilation. Neither age nor FEV1 should be used in isolation when assessing suitability.NIV should be considered for patients who are slow to wean from invasive ventilation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8343", "name": "intravenous theophylline", "draggable": "true", "value": {"name": "intravenous theophylline", "type": "treatment related", "time": "", "intention": "", "description": "title:intravenous theophyllinehead:Intravenous theophyllineIntravenous theophylline should only be used as an adjunct to the management of exacerbations of COPD if there is an inadequate response to nebulised bronchodilators.Care should be taken when using intravenous theophylline because of interactions with other drugs and potential toxicity if the patient has been on oral theophylline.Theophylline levels should be monitored within 24 hours of starting treatment and subsequently as frequently as indicated by the clinical circumstances.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8359", "name": "combined inhaled and oral therapies", "draggable": "true", "value": {"name": "combined inhaled and oral therapies", "type": "treatment related", "time": "", "intention": "", "description": "title:combined inhaled and oral therapieshead:Combined inhaled and oral therapiesIf patients remain symptomatic on monotherapy, their treatment should be intensified by combining therapies from different drug classes. Effective combinations include: beta2 agonist and theophylline anticholinergic and theophylline.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8330", "name": "managing stable copd", "draggable": "true", "value": {"name": "managing stable copd", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing stable copd", "drug": {}}}, {"category": "treatment", "id": "t8328", "name": "managing co existing conditions", "draggable": "true", "value": {"name": "managing co existing conditions", "type": "treatment related", "time": "", "intention": "digoxin\nalso has been used for management of paroxysmal supraventricular tachycardia (psvt) due to av nodal reentry tachycardia (avnrt) or av reentry tachycardia (avrt).700\npossibility of inadvertent overdosage when a tuberculin syringe is used to measure very small doses; exercise caution.b 400 401\npeak digoxin body stores exceeding the 8\u201312 mcg/kg required for most patients with heart failure and normal sinus rhythm have been used for control of ventricular rate in patients with atrial fibrillation.b 401 402 in the treatment of chronic atrial fibrillation, titrate dosage to the minimum dosage that achieves the desired ventricular rate control without causing undesirable adverse effects.401 402 appropriate target resting or exercising rates have not been established.401 402\npeak digoxin body stores exceeding the 8\u201312 mcg/kg required for most patients with heart failure and normal sinus rhythm have been used for control of ventricular rate in patients with atrial fibrillation.b 398 399 400 403", "description": "title:managing co-existing conditionshead:Managing co-existing conditionssubhead:Alpha-1 antitrypsin deficiencyAlpha-1 antitrypsin replacement therapy is not recommended for patients with alpha-1 antitrypsin deficiency (see also when to refer).subhead:Cor pulmonaleA diagnosis of cor pulmonale should be considered if patients have: peripheral oedema a raised venous pressure a systolic parasternal heave a loud pulmonary second heart sound.It is recommended that the diagnosis of cor pulmonale is made clinically and that this process should involve excluding other causes of peripheral oedema.Patients presenting with cor pulmonale should be assessed for the need for LTOT.Oedema associated with cor pulmonale can usually be controlled symptomatically with diuretic therapy.The following are not recommended for the treatment of cor pulmonale: angiotensin-converting enzyme inhibitors calcium channel blockers alpha-blockers digoxin (unless there is atrial fibrillation).subhead:Low body mass indexBMI should be calculated in patients with COPD: If the BMI is low patients should also be given nutritional supplements to increase their total calorific intake and be encouraged to take exercise to augment the effects of nutritional supplementation.For information on nutrition support in adults who are malnourished or at risk of malnutrition see NICE s recommendations on nutrition support in adults.For information on weight loss see NICE s recommendations on obesity.subhead:Multiple long-term conditionsFor further information, see NICE s recommendations on multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {"digoxin": "DB00390", "calcium": "DB00884"}}}, {"category": "treatment", "id": "t8329", "name": "managing exacerbations", "draggable": "true", "value": {"name": "managing exacerbations", "type": "treatment related", "time": "", "intention": "", "description": "title:managing exacerbations", "drug": {}}}, {"category": "treatment", "id": "t8346", "name": "monitoring in hospital", "draggable": "true", "value": {"name": "monitoring in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:monitoring in hospitalhead:Monitoring in hospital Patients  recovery should be monitored by regular clinical assessment of their symptoms and observation of their functional capacity.Pulse oximetry should be used to monitor the recovery of patients with non-hypercapnic, non-acidotic respiratory failure.Intermittent arterial blood gas measurements should be used to monitor the recovery of patients with respiratory failure who are hypercapnic or acidotic, until they are stable.Daily monitoring of PEF or FEV1 should not be performed routinely to monitor recovery from an exacerbation because the magnitude of changes is small compared with the variability of the measurement.subhead:Nasal Alar SpO2 sensorNICE has published a medtech innovation briefing on Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8360", "name": "surgery", "draggable": "true", "value": {"name": "surgery", "type": "treatment related", "time": "", "intention": "", "description": "title:surgeryhead:Surgerysubhead:General considerations regarding surgery The ultimate clinical decision about whether or not to proceed with surgery should rest with a consultant anaesthetist and consultant surgeon taking account of the presence of comorbidities, the functional status of the patient and the necessity of the surgery.It is recommended that lung function should not be the only criterion used to assess patients with COPD before surgery. Composite assessment tools such as the ASA scoring system are the best predictors of risk.If time permits, the medical management of the patient should be optimised prior to surgery and this might include undertaking a course of pulmonary rehabilitation. See pulmonary rehabilitation.See NICE s recommendations on preoperative tests.subhead:BullectomyPatients who are breathless, and have a single large bulla on a CT scan and an FEV1 less than 50% predicted should be referred for consideration of bullectomy.subhead:Lung volume reduction surgeryPatients with severe COPD who remain breathless with marked restrictions of their activities of daily living, despite maximal medical therapy (including rehabilitation), should be referred for consideration of lung volume reduction surgery if they meet all of the following criteria: FEV1 more than 20% predicted PaCO2 less than 7.3 kPa upper lobe predominant emphysema TLCO more than 20% predicted.subhead:Interventional proceduresNICE has published guidance on: endobronchial valve insertion to reduce lung volume in emphysema with standard arrangements for clinical governance, consent and audit  lung volume reduction surgery for advanced emphysema with normal arrangements for consent, audit and clinical governance insertion of endobronchial nitinol coils to improve lung function in emphysema which should be used only in the context of research.subhead:Lung transplantationPatients with severe COPD who remain breathless with marked restrictions of their activities of daily living despite maximal medical therapy should be considered for referral for assessment for lung transplantation bearing in mind comorbidities and local surgical protocols. Considerations include: age FEV1 PaCO2 homogeneously distributed emphysema on CT scan elevated pulmonary artery pressures with progressive deterioration.NICE has published interventional procedures guidance on living-donor lung transplantation for end-stage lung disease (see guidance for details). SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8361", "name": "follow up", "draggable": "true", "value": {"name": "follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:follow-uphead:Follow-upFollow-up of all patients with COPD should include: highlighting the diagnosis of COPD in the case record and recording this using read codes on a computer database recording the values of spirometric tests performed at diagnosis (both absolute and percent predicted) offering smoking cessation advice recording the opportunistic measurement of spirometric parameters (a loss of 500 ml or more over 5 years will select out those patients with rapidly progressing disease who may need specialist referral and investigation).Patients with COPD should be reviewed at least once per year, or more frequently if indicated, and the review should cover the issues listed in the summary of follow-up of patients with COPD in primary care.For most patients with stable severe disease regular hospital review is not necessary, but there should be locally agreed mechanisms to allow rapid access to hospital assessment when necessary.When patients with very severe COPD are reviewed in primary care, they should be seen at least twice a year, and specific attention should be paid to the issues listed in the summary of follow-up of patients with COPD in primary care.Patients with severe disease requiring interventions such as long-term NIV should be reviewed regularly by specialists.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8347", "name": "discharge from hospital", "draggable": "true", "value": {"name": "discharge from hospital", "type": "information and support", "time": "", "intention": "", "description": "title:discharge from hospitalhead:Discharge from hospitalSpirometry should be measured in all patients before discharge.Patients should be re-established on their optimal maintenance bronchodilator therapy before discharge.Patients who have had an episode of respiratory failure should have satisfactory oximetry or arterial blood gas results before discharge.All aspects of the routine care that patients receive (including appropriateness and risk of side effects) should be assessed before discharge.Patients (or home carers) should be given appropriate information to enable them to fully understand the correct use of medications, including oxygen, before discharge.Arrangements for follow-up and home care (such as visiting nurse, oxygen delivery, referral for other support) should be made before discharge.Before the patient is discharged, the patient, family and physician should be confident that he or she can manage successfully. When there is remaining doubt a formal activities of daily living assessment may be helpful.For information about reducing the risk of death and ill health associated with living in a cold home, see NICE s recommendations on excess winter deaths and illnesses associated with cold homes. See also NICE s recommendations on home care for older people.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.Chronic obstructive pulmonary disease in adults quality standard2Inhaler techniqueSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG101", "drug": {}}}, {"category": "treatment", "id": "t8362", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8348", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "drug", "id": "d25", "name": "alli", "draggable": "true", "value": {"name": "alli", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d86", "name": "beta-carotene", "draggable": "true", "value": {"name": "beta-carotene", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d108", "name": "bupropion", "draggable": "true", "value": {"name": "bupropion", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d167", "name": "aclidinium bromide", "draggable": "true", "value": {"name": "aclidinium bromide", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d297", "name": "fluticasone", "draggable": "true", "value": {"name": "fluticasone", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d181", "name": "commit", "draggable": "true", "value": {"name": "commit", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d232", "name": "doxapram", "draggable": "true", "value": {"name": "doxapram", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d222", "name": "digoxin", "draggable": "true", "value": {"name": "digoxin", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d118", "name": "calcium", "draggable": "true", "value": {"name": "calcium", "time": "None", "period": "None", "dosage": "None"}}]}